Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 36
- Registration Number
- NCT00784927
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
- Conditions
- Follicular LymphomaMarginal Zone B-Cell LymphomaMALT LymphomaLymphoma of Mucosa-Associated Lymphoid TissueLymphoma, Small LymphocyticWaldenstrom MacroglobulinemiaMantle-Cell Lymphoma
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 50
- Registration Number
- NCT00783367
- Locations
- 🇺🇸
University of Pennsylvania; Abramson Cancer Center; Lymphoma Program, Philadelphia, Pennsylvania, United States
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
- Conditions
- Choroidal NeovascularizationAge-Related Maculopathy
- Interventions
- Drug: dexamethasoneBiological: ranibizumab
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Allergan
- Target Recruit Count
- 44
- Registration Number
- NCT00775411
Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 143
- Registration Number
- NCT00773838
Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 39
- Registration Number
- NCT00772915
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2014-10-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 103
- Registration Number
- NCT00770562
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: dexamethasoneDrug: daunorubicin hydrochlorideDrug: doxorubicin hydrochlorideDrug: methotrexateDrug: mercaptopurineDrug: thioguanineDrug: etoposideDrug: vincristine sulfateDrug: ifosfamideDrug: leucovorin calciumDrug: prednisoneDrug: vindesine
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- University Hospital, Motol
- Target Recruit Count
- 4000
- Registration Number
- NCT00764907
- Locations
- 🇨🇿
University Hospital Motol, Prague, Czech Republic
Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive
- Conditions
- Leukemia, Lymphocytic, AcutePhiladelphia ChromosomeBlast CrisisLeukemia, Myeloid, Chronic
- Interventions
- First Posted Date
- 2008-10-01
- Last Posted Date
- 2011-10-05
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 55
- Registration Number
- NCT00763763
- Locations
- 🇫🇷
Service Clinique des Maladies du Sang, Paris, France
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 35
- Registration Number
- NCT00742404
- Locations
- 🇺🇸
James R. Berenson MD, Incorporated, West Hollywood, California, United States
🇺🇸San Diego Pacific Oncology and Hematology Associates, Incorporated - Escondido, Escondido, California, United States
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2008-08-25
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 39
- Registration Number
- NCT00740415
- Locations
- 🇫🇷
CHU de Grenoble - Hopital Michallon, Grenoble, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.